Skip to main content

Genaissance Licenses Pharmacogenomic Technology to Millennium

NEW YORK, Jan. 7-Genaissance Pharmaceuticals has licensed its HAP pharmacogenomic platform to Millennium Pharmaceuticals, the company said today.

 

The agreement is a non-exclusive, multi-year agreement under which Genaissance will receive license fees from Millennium. Further financial details were not disclosed.

 

For further information, see the company statement.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.